

Ian Campbell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11334689/publications.pdf>

Version: 2024-02-01

44
papers

589
citations

567281

15
h-index

677142

22
g-index

44
all docs

44
docs citations

44
times ranked

704
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of breast reconstruction choice on body image patient-reported outcomes at four years post-mastectomy for breast cancer: A longitudinal prospective cohort study. <i>Psycho-Oncology</i> , 2022, 31, 54-61.	2.3	8
2	Differences in Breast Cancer Costs by Cancer Stage and Biomarker Subtype in New Zealand. <i>PharmacoEconomics - Open</i> , 2022, , 1.	1.8	2
3	Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 225-235.	2.5	5
4	Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand. <i>Breast Cancer</i> , 2021, 28, 387-397.	2.9	12
5	Associated Factors and Survival Outcomes for Breast Conserving Surgery versus Mastectomy among New Zealand Women with Early-Stage Breast Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2738.	2.6	7
6	Metastatic relapse of stage III breast cancer in New Zealand. <i>Cancer Causes and Control</i> , 2021, 32, 753-761.	1.8	5
7	Impact of menopausal status on risk of metastatic recurrence of breast cancer. <i>Menopause</i> , 2021, 28, 1085-1092.	2.0	10
8	Breast cancer costs in New Zealand's public health system. <i>New Zealand Medical Journal</i> , 2021, 134, 36-46.	0.5	2
9	Use and results of systemic treatments for de novo and recurrent metastatic breast cancer: a population-based cohort study. <i>New Zealand Medical Journal</i> , 2021, 134, 47-59.	0.5	0
10	Receipt of radiotherapy after mastectomy in women with breast cancer: Population-based cohort study in New Zealand. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e99-e107.	1.1	2
11	Psychosocial support needs of women with breast cancer in the Waikato region of New Zealand. <i>Psycho-Oncology</i> , 2020, 29, 1971-1974.	2.3	0
12	Treatment and survival of Asian women diagnosed with breast cancer in New Zealand. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 497-505.	2.5	19
13	Outcomes in different ethnic groups of New Zealand patients with screen-detected vs. non-screen-detected breast cancer. <i>Journal of Medical Screening</i> , 2019, 26, 197-203.	2.3	4
14	Impact of radiotherapy on cardiovascular health of women with breast cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 250-256.	1.8	0
15	Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 316-324.	0.8	50
16	The characteristics, management and outcomes of older women with breast cancer in New Zealand. <i>Maturitas</i> , 2018, 112, 64-70.	2.4	7
17	The use of trastuzumab in New Zealand women with breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e152-e160.	1.1	9
18	Surgical treatment of early stage breast cancer in the Auckland and Waikato regions of New Zealand. <i>ANZ Journal of Surgery</i> , 2018, 88, 1263-1268.	0.7	8

#	ARTICLE	IF	CITATIONS
19	Development and validation of a new predictive model for breast cancer survival in New Zealand and comparison to the Nottingham prognostic index. <i>BMC Cancer</i> , 2018, 18, 897.	2.6	15
20	In Reply to Belkacemi and Tsoutsou. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 467-468.	0.8	0
21	Ethnic disparities in breast cancer survival in New Zealand: which factors contribute?. <i>BMC Cancer</i> , 2018, 18, 58.	2.6	33
22	Obesity and breast cancer outcomes in chemotherapy patients in New Zealand – a population-based cohort study. <i>BMC Cancer</i> , 2018, 18, 76.	2.6	10
23	The impact of different tumour subtypes on management and survival of New Zealand women with Stage I-III breast cancer. <i>New Zealand Medical Journal</i> , 2018, 131, 51-60.	0.5	14
24	Ethnic, socio-demographic and socio-economic differences in surgical treatment of breast cancer in New Zealand. <i>ANZ Journal of Surgery</i> , 2017, 87, E32-E39.	0.7	20
25	A cohort study of ethnic differences in use of adjuvant chemotherapy and radiation therapy for breast cancer in New Zealand. <i>BMC Health Services Research</i> , 2017, 17, 64.	2.2	4
26	Treatment and survival disparities by ethnicity in New Zealand women with stage I-III breast cancer tumour subtypes. <i>Cancer Causes and Control</i> , 2017, 28, 1417-1427.	1.8	19
27	Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? Five-Year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial: Assessment and Incidence of True Lymphedema. <i>Annals of Surgical Oncology</i> , 2017, 24, 1064-1070.	1.5	33
28	Urban Rural Differences in Breast Cancer in New Zealand. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 1000.	2.6	7
29	Differences in Breast Cancer Survival between Public and Private Care in New Zealand: Which Factors Contribute?. <i>PLoS ONE</i> , 2016, 11, e0153206.	2.5	17
30	Stage of breast cancer at diagnosis in New Zealand: impacts of socio-demographic factors, breast cancer screening and biology. <i>BMC Cancer</i> , 2016, 16, 129.	2.6	40
31	Initial axillary surgery: results from the BreastSurgANZ Quality Audit. <i>ANZ Journal of Surgery</i> , 2015, 85, 777-782.	0.7	4
32	Breast Cancer Biology and Ethnic Disparities in Breast Cancer Mortality in New Zealand: A Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0123523.	2.5	18
33	Development and piloting of a decision aid for women considering participation in the Sentinel Node Biopsy versus Axillary Clearance 2 breast cancer trial. <i>Clinical Trials</i> , 2015, 12, 409-417.	1.6	8
34	Ethnic differences in breast cancer survival in New Zealand: contributions of differences in screening, treatment, tumor biology, demographics and comorbidities. <i>Cancer Causes and Control</i> , 2015, 26, 1813-1824.	1.8	19
35	Adherence to adjuvant endocrine therapy: Is it a factor for ethnic differences in breast cancer outcomes in New Zealand?. <i>Breast</i> , 2015, 24, 62-67.	2.2	22
36	Treatment delay for Māori women with breast cancer in New Zealand. <i>Ethnicity and Health</i> , 2015, 20, 178-193.	2.5	29

#	ARTICLE	IF	CITATIONS
37	Impact of mammographic screening on ethnic and socioeconomic inequities in breast cancer stage at diagnosis and survival in New Zealand: a cohort study. BMC Public Health, 2015, 15, 46.	2.9	31
38	To infiltrate or not? Acute effects of local anaesthetic in breast surgery. ANZ Journal of Surgery, 2015, 85, 353-357.	0.7	20
39	Final analysis of a randomized comparison of letrozole (Let) vs observation (Obs) as late reintroduction of adjuvant endocrine therapy (AET) for postmenopausal women with hormone receptor positive (HR+) breast cancer (BC) after completion of prior AET: ANZBCTG 0501 (LATER).. Journal of Clinical Oncology, 2015, 33, 514-514.	1.6	2
40	Breast Cancer Characteristics and Survival Differences between Maori, Pacific and other New Zealand Women Included in the Quality Audit Program of Breast Surgeons of Australia and New Zealand. Asian Pacific Journal of Cancer Prevention, 2015, 16, 2465-2472.	1.2	16
41	Contralateral prophylactic mastectomy (CPM) use and utility in New Zealand (NZ) breast cancer patients.. Journal of Clinical Oncology, 2015, 33, e17671-e17671.	1.6	0
42	Contralateral breast cancer (CBC) incidence and risk in New Zealand (NZ).. Journal of Clinical Oncology, 2015, 33, e17669-e17669.	1.6	0
43	Ethnic differences in timely adjuvant chemotherapy and radiation therapy for breast cancer in New Zealand: a cohort study. BMC Cancer, 2014, 14, 839.	2.6	20
44	Accuracy and completeness of the New Zealand Cancer Registry for staging of invasive breast cancer. Cancer Epidemiology, 2014, 38, 638-644.	1.9	38